Jörn M. Schattenberg
YOU?
Author Swipe
View article: Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study.
Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study. Open
Aims Endothelin A (ETA) receptor antagonists may reduce cirrhosis-associated portal hypertension (PH). They are associated with fluid retention, which might be mitigated by sodium-glucose co-transporter 2 inhibitors (SGLT2is). Efficacy, sa…
View article: Psychosocial Work Stress, Resilience and the Risk of Tinnitus—Results from a Population-Based Cohort Study
Psychosocial Work Stress, Resilience and the Risk of Tinnitus—Results from a Population-Based Cohort Study Open
Background and Objectives: Tinnitus is a common symptom in otolaryngologic practice. Although its pathophysiology is multifactorial and remains mostly unclear, it can be correlated to stress and psychological comorbidities. The aim of this…
View article: Joint Bacterial Traces in the Gut and Oral Cavity of Obesity Patients Provide Evidence for Saliva as a Rich Microbial Biomarker Source
Joint Bacterial Traces in the Gut and Oral Cavity of Obesity Patients Provide Evidence for Saliva as a Rich Microbial Biomarker Source Open
Background: The human microbiome holds promise for identifying biomarkers and therapeutic targets. In obesity, interactions between oral and gut communities are increasingly implicated and end in organ injury. Methods: From the IMAGINE stu…
View article: Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes
Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes Open
Importance Metabolic dysfunction–associated steatohepatitis (MASH) represents a high, underprioritized burden among noncommunicable diseases (NCDs) and people living with type 2 diabetes (T2D). Objective To identify cost-effective manageme…
View article: Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD
Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD Open
Non-invasive tests (NITs) facilitate the early diagnosis and management of clinically significant portal hypertension in patients with compensated advanced chronic liver disease (cACLD). In our contemporary cohort of patients with cACLD, m…
View article: Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management
Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management Open
Steatotic liver disease (SLD) is a leading cause of disease globally and demands new therapeutic approaches to mitigate underlying metabolic dysregulation. Incretin-based therapies are emerging as a viable prospect to fulfil this unmet nic…
View article: Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care
Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care Open
Pruritus in patients with PBC is common and under-treated in the real-world scenario. Assessment and management vary by healthcare level, highlighting the need for standardized care and greater awareness of treatment options across all set…
View article: Incidence of major cardiovascular events in patients with metabolic dysfunction‐associated steatotic liver disease in the general population
Incidence of major cardiovascular events in patients with metabolic dysfunction‐associated steatotic liver disease in the general population Open
Aims Major adverse cardiovascular events (MACE) related to cardiovascular disease are a major cause of death in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). We explored the impact of MASLD on incident MAC…
View article: Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis
Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis Open
Background and Aims The role of the patatin‐like phospholipase domain‐containing protein 3 (PNPLA3)‐I148M variant in drug‐induced liver injury (DILI) remains unclear. This systematic review with meta‐analysis investigated whether carriage …
View article: Hepatic Inflammation and Liver Injury in a Model of Bacterial Infection Triggered Acute‐on‐Chronic Liver Injury
Hepatic Inflammation and Liver Injury in a Model of Bacterial Infection Triggered Acute‐on‐Chronic Liver Injury Open
Background and Aim Acute‐on‐chronic liver failure (ACLF) is characterized by acute decompensation of chronic liver disease in the presence of an acute trigger, and bacterial infection (BI) is the most common trigger of ACLF. Therefore, we …
View article: Limitations of Guideline‐Recommended Risk Stratification in Identifying <scp>MASLD</scp> Patients for Novel Drug Treatments
Limitations of Guideline‐Recommended Risk Stratification in Identifying <span>MASLD</span> Patients for Novel Drug Treatments Open
Current guidelines recommend FIB‐4 and transient elastography for non‐invasive risk stratification in metabolic dysfunction‐associated steatotic liver disease (MASLD). These tests can predict the presence or absence of advanced fibrosis, b…
View article: A Comparison of the Predictive Value of 12 Body Composition Markers for Metabolic Dysfunction-Associated Steatotic Liver Disease, At-Risk Metabolic Dysfunction-Associated Steatohepatitis, and Increased Liver Stiffness in a General Population Setting
A Comparison of the Predictive Value of 12 Body Composition Markers for Metabolic Dysfunction-Associated Steatotic Liver Disease, At-Risk Metabolic Dysfunction-Associated Steatohepatitis, and Increased Liver Stiffness in a General Population Setting Open
INTRODUCTION: Adipose tissue is a key mediator of metabolic dysfunction-associated steatotic liver disease (MASLD) development and progression into metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Since direct comparis…
View article: Metabolic Dysfunction–Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel
Metabolic Dysfunction–Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel Open
Background Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major cause of chronic liver disease. Metabolic dysfunction‐associated steatohepatitis (MASH), a progressive form of MASLD, can lead to fibrosis and cirrhosis…
View article: Clinical Utility of Non‐Invasive Tests for Liver Fibrosis in People Living With Alpha‐1 Antitrypsin Deficiency
Clinical Utility of Non‐Invasive Tests for Liver Fibrosis in People Living With Alpha‐1 Antitrypsin Deficiency Open
Severe alpha‐1 antitrypsin deficiency (AATD) is a rare genetic condition characterised by low systemic levels of alpha‐1 antitrypsin due to its retention in the liver. Consequently, it predisposes individuals to the development of chronic …
View article: Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre study
Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre study Open
Introduction The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) may be as high as 38% in the adult population with potential serious complications, multiple comorbidities and a high socioeconomic burden. How…
View article: Joint bacterial traces in the gut and oral cavity of Colitis patients provide evidence for saliva as rich microbial biomarker source
Joint bacterial traces in the gut and oral cavity of Colitis patients provide evidence for saliva as rich microbial biomarker source Open
The human microbiome, distributed across various anatomical sites, holds promise for identifying diagnostic biomarkers and therapeutic targets in disease. In inflammatory bowel disease (IBD), including ulcerative colitis (UC), interactions…
View article: Global Burden of Major Chronic Liver Diseases in 2021
Global Burden of Major Chronic Liver Diseases in 2021 Open
Background This study utilised the Global Burden of Disease data (2010–2021) to analyse the rates and trends in point prevalence, annual incidence and years lived with disability (YLDs) for major chronic liver diseases, such as hepatitis B…
View article: Revolutionizing MASLD: How Artificial Intelligence Is Shaping the Future of Liver Care
Revolutionizing MASLD: How Artificial Intelligence Is Shaping the Future of Liver Care Open
Metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as a leading cause of chronic liver disease. In recent years, artificial intelligence (AI) has attracted significant attention in healthcare, particularly in diag…